AIGH Capital Management LLC cut its stake in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 23.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,326,569 shares of the company's stock after selling 700,000 shares during the period. Theratechnologies accounts for 1.3% of AIGH Capital Management LLC's holdings, making the stock its 23rd largest position. AIGH Capital Management LLC owned about 5.06% of Theratechnologies worth $3,257,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently bought and sold shares of the stock. Hillsdale Investment Management Inc. acquired a new stake in shares of Theratechnologies in the fourth quarter valued at approximately $108,000. Cyndeo Wealth Partners LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at approximately $42,000. Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the fourth quarter valued at approximately $40,000. BNP Paribas Financial Markets acquired a new stake in shares of Theratechnologies in the fourth quarter valued at approximately $36,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Theratechnologies in the fourth quarter valued at approximately $33,000.
Theratechnologies Stock Up 0.5%
Shares of NASDAQ THTX traded up $0.02 during midday trading on Friday, reaching $3.17. 117,003 shares of the company were exchanged, compared to its average volume of 1,565,051. Theratechnologies Inc. has a one year low of $1.12 and a one year high of $3.20. The stock has a market cap of $145.53 million, a P/E ratio of -16.66 and a beta of 0.55. The stock's 50-day moving average price is $2.73 and its 200-day moving average price is $2.19.
Theratechnologies (NASDAQ:THTX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 9th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). The firm had revenue of $17,729 billion for the quarter, compared to analysts' expectations of $24.30 million. On average, equities research analysts anticipate that Theratechnologies Inc. will post 0.01 EPS for the current year.
Analysts Set New Price Targets
Separately, Jones Trading cut shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.
Read Our Latest Research Report on THTX
About Theratechnologies
(
Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Stories
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access